What is the official website of Novartis ?

The official website of Novartis is http://www.novartis.com.

What is Novartis's cybersecurity risk score?

Novartis has an AI-generated cybersecurity risk score of 811 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Novartis experienced?

According to Rankiteo, Novartis currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis is not certified under SOC 2 Type 1.

Does Novartis have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis does not hold a SOC 2 Type 2 certification.

Does Novartis comply with GDPR ?

According to Rankiteo, Novartis is not listed as GDPR compliant.

Does Novartis have PCI DSS certification ?

According to Rankiteo, Novartis does not currently maintain PCI DSS compliance.

Does Novartis comply with HIPAA ?

According to Rankiteo, Novartis is not compliant with HIPAA regulations.

Does Novartis have ISO 27001 certification ?

According to Rankiteo,Novartis is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis operate in ?

Novartis operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis have ?

Novartis employs approximately 86,785 people worldwide.

Does Novartis own any subsidiaries ?

Novartis presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis have ?

Novartis's official LinkedIn profile has approximately 4,751,735 followers.

What is the NAICS classification code for Novartis ?

Novartis is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis have a Crunchbase profile ?

No, Novartis does not have a profile on Crunchbase.

Does Novartis have a LinkedIn profile ?

Yes, Novartis maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis.

How many cybersecurity incidents has Novartis experienced ?

As of August 7, 2026, Rankiteo reports that Novartis has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis have ?

Novartis has an estimated 5,725 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis

Boost Score +25 with badge (5 left)

811

/1000

Good

836

/1000

Good

Novartis Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Novartis A.I CyberSecurity Scoring

Scoring History

Novartis

Novartis CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis has 34.64% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

Novartis has 2.91% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types Novartis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 0 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.

Incident History - Novartis (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Subsidiaries

Novartis

Pharmaceutical Manufacturing

Website: http://www.novartis.com

Company Size: 10,001+ employees

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Loading…

Novartis Similar Companies

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Loading…

NEWS

Novartis CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

August 03, 2026 03:05 PM

Amgen says patient health data, IP stolen in cybersecurity breach

Hackers recently accessed Amgen's cloud environment, stealing patient health information and proprietary company data,...

Read Article

July 28, 2026 02:40 PM

Cognizant Bags 5-Year IT Operations Deal With Novartis

Cognizant has secured a five-year contract to manage IT operations for global pharmaceutical giant Novartis. The partnership will use...

Read Article

May 21, 2026 07:00 AM

BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more.

Read Article

May 20, 2026 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

May 06, 2026 07:00 AM

Review cyber risks in 2 months: RBI to banks

Reserve Bank of India asks banks to review cybersecurity readiness within two months amid rising AI-driven threats and system...

Read Article

April 15, 2026 07:00 AM

Who is Vas Narasimhan, the Indian-origin Novartis CEO who joined Anthropic's board

The Indian-origin pharma executive is the first healthcare professional to sit on the board of the AI startup and his appointment points to...

Read Article

March 25, 2026 07:00 AM

Novartis sued for allegedly leaking data on breast cancer patient to Google, Contentsquare

In a lawsuit seeking class action status, a woman identified as “P.M.” said she began using the website for Kisqali, a Novartis breast...

Read Article

March 24, 2026 07:00 AM

Novartis Sued Over Tracking Pixels on Drug-Discount Websites

A Vermont breast cancer patient sued Novartis Pharmaceuticals Corp. for allegedly sharing her health information with Google LLC and other...

Read Article

March 23, 2026 07:00 AM

Novartis Faces Class Suit Over Patient Health Info Disclosure

Drugmaker Novartis collected patients' personal and health information through pharmaceutical marketing websites and transmitted it to third...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8325

SUMMARY

A maliciously crafted PDF file, when parsed through Autodesk Revit, can force an Out-of-Bounds Write vulnerability. A malicious actor may leverage this vulnerability to cause a crash, cause data corruption, or execute arbitrary code in the context of the current process.

Published

Date2026-08-06

Updated

Date2026-08-06

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-7867

SUMMARY

A flaw was found in udisks2. A local attacker with an active console session can exploit insufficient authorization checking on the 'as-user' option in the org.freedesktop.UDisks2.Filesystem.Mount() D-Bus method. This allows the attacker to spoof the 'as-user' parameter, mounting filesystems on behalf of arbitrary users, including privileged accounts. This can lead to local privilege escalation through mount point injection and manipulation of the mount namespace visible to privileged users.

Published

Date2026-08-06

Updated

Date2026-08-06

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-7406

SUMMARY

A maliciously crafted BMP file, when parsed through certain Autodesk products, can force a Untrusted Pointer Dereference vulnerability. A malicious actor can leverage this vulnerability to execute arbitrary code in the context of the current process.

Published

Date2026-08-06

Updated

Date2026-08-06

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-7405

SUMMARY

A maliciously crafted TIF file, when parsed through certain Autodesk products during image import, can cause an Out-of-Bounds Read in the image handling library. A malicious actor can leverage this vulnerability to cause a denial of service

Published

Date2026-08-06

Updated

Date2026-08-06

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-71555

SUMMARY

PILOS (Platform for Interactive Live-Online Seminars) is a frontend for BigBlueButton. From 2.1.0 until 4.14.1, PILOS does not send a Cross-Origin-Opener-Policy response header, so pages opened by PILOS via a link that opens a new browsing context (e.g., target="_blank") retain a window.opener reference back to the originating PILOS tab. A malicious destination page reached this way can use window.opener to navigate or manipulate the original PILOS tab, a technique known as reverse tabnabbing, potentially redirecting an authenticated user to a phishing page that mimics PILOS. This issue is fixed in version 4.14.1.

Published

Date2026-08-06

Updated

Date2026-08-06

RISK INFORMATION (Score: 4.1)

cvss3

Base Score: 4.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…